NuCana Announced Interim Data from First-In-Human Study of Transformative Anti-Cancer Agent, NUC-3373 and Received Best Poster Presentation Award at ESMO 2017. Read More. Edinburgh: September 2017. NuCana Announced Positive Results of NUC-1031 (Acelarin ®) in Advanced Ovarian Cancer at ESMO 2017.
Цааш унших